What is HEPION PHARMS INC's earnings per share (EPS)?

HEPION PHARMS INC (HEPA) reported diluted earnings per share of -$0.88 for fiscal year 2025. This represents a 99.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

HEPION PHARMS INC (HEPA) Financials

HEPA

FY2025 annual

Revenue Not reported for FY2025

Net Income -$8.3M YoY not available

EPS (Diluted) -$0.88 +99.2% YoY

Operating Cash Flow -$3.3M YoY not available

Market Cap $12.8M as of Oct 16, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 10.0x on $1.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HEPA SEC filings page.

This page shows HEPION PHARMS INC (HEPA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HEPA FY2025 2026-10-04

Hepion has no reported revenue, so its 2025 activity is financed by capital while operations continue consuming cash.

Liquidity swung from a 0.5x current ratio in FY2024 to 10.3x in FY2025, indicating a much less constrained short-term balance sheet. But FY2025 operating cash flow was -$3.3M against financing cash flow of $4.8M; the improvement came from external capital, not operating receipts.

The absence of reported revenue through FY2025 makes margin analysis uninformative; the business is still measured by spending and funding rather than sales economics. R&D was $35.6M in FY2023 but only $446K in FY2025, showing a sharply smaller reported development outlay rather than evidence of commercial revenue.

FY2025 ended with a net loss of $8.3M and a return on assets of -269.6%. With total assets of $3.1M, the result reflects a very small asset base relative to the reported annual loss.

Financial Health Signals

Financial health score not available

HEPION PHARMS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/5

HEPION PHARMS INC passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

HEPION PHARMS INC reported a net loss of $8.3M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

HEPION PHARMS INC reported an operating loss of $4.2M against $24K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$1.2M

YoY-19.7%

QoQ-54.0%

HEPION PHARMS INC reported -$1.2M in net income in Q2 2026. This represents a decrease of 19.7% from the same quarter a year earlier. Against the prior quarter it is down 54.0%.

EPS (Diluted)

-$0.08

HEPION PHARMS INC earned -$0.08 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$1.6M

YoY-44.3%

QoQ-37.4%

5Y CAGR-56.9%

10Y CAGR-14.1%

HEPION PHARMS INC held $1.6M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

90M

5Y CAGR+3.4%

10Y CAGR+5.3%

HEPION PHARMS INC had 90M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-97.6%

YoY-70.2pp

QoQ-54.0pp

HEPION PHARMS INC's ROE was -97.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 70.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 54.0 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$51K

YoY-88.0%

QoQ-27.3%

HEPION PHARMS INC invested $51K in research and development in Q2 2026. This represents a decrease of 88.0% from the same quarter a year earlier. Against the prior quarter it is down 27.3%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

HEPA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HEPA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1410-K
Revenue	N/A	N/A	N/A	$0	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$446K	N/A	$35.6M+7.1%	$33.3M+63.1%	$20.4M+70.0%	$12.0M+276.8%	$3.2M-58.1%	$7.6M-43.2%	$13.4M-11.0%	$15.0M+78.7%	$8.4M+2574.2%	$314K	$113K
SG&A Expenses	N/A	$3.3M-55.8%	$7.5M-22.0%	$9.6M-7.1%	$10.3M+3.4%	$10.0M+22.8%	$8.1M+77.7%	$4.6M-34.5%	$7.0M-3.8%	$7.3M+25.8%	$5.8M+4.1%	$5.6M+309.2%	$1.4M	$830K
Operating Income	N/A	-$4.2M	N/A	-$48.4M-6.5%	-$45.5M-49.6%	-$30.4M-50.9%	-$20.1M-159.3%	-$7.8M+46.8%	-$14.6M+29.3%	-$20.6M+0.8%	-$20.8M-49.0%	-$14.0M-734.9%	-$1.7M	-$943K
EBITDA	N/A	N/A	N/A	-$48.4M-6.5%	-$45.4M-49.8%	-$30.3M-50.7%	-$20.1M-159.7%	-$7.7M+46.9%	-$14.6M+29.3%	-$20.6M+0.8%	-$20.8M-49.1%	-$13.9M-734.6%	-$1.7M	N/A
Interest Expense	N/A	$24K-98.0%	$1.2M+13078.2%	$9K-6.9%	$10K+14.7%	$9K-71.6%	$31K-94.4%	$555K+63.6%	$339K	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	-$3.0M-625.9%	-$409K+85.8%	-$2.9M	$0-100.0%	$31K+103.4%	-$909K-69.5%	-$536K+72.5%	-$1.9M	N/A	$0	$0	N/A
Net Income	N/A	-$8.3M	N/A	-$48.9M-15.9%	-$42.2M-29.0%	-$32.7M-60.8%	-$20.4M-189.2%	-$7.0M+25.5%	-$9.4M+36.5%	-$14.9M+12.4%	-$17.0M-18.5%	-$14.3M-171.7%	-$5.3M	-$9.8M
EPS (Basic)	N/A	-$0.88+99.2%	-$107.35+82.6%	-$616.07-5077.1%	-$11.90-2431.9%	-$0.47+77.6%	-$2.10+64.7%	-$5.95+93.9%	-$97.35-4672.1%	-$2.04-223.8%	-$0.63	N/A	N/A	N/A
EPS (Diluted)	—	-$0.88+99.2%	-$107.35	-$616.07	-$11.90	-$0.47	-$2.10	N/A	-$1.39	-$2.41	-$0.63	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	9M+7556.5%	122,894	79,416	4M	70M	10M	N/A	13M	7M	27M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$51K-88.0%	$70K+214.8%	N/A	N/A	$423K-94.1%	$22K-99.1%	N/A	$2.8M-67.6%
SG&A Expenses	$1.2M+26.2%	$729K-42.1%	N/A	$528K-68.9%	$919K-32.7%	$1.3M-52.4%	N/A	$1.7M-21.0%
Operating Income	-$1.2M+30.6%	-$799K+37.6%	N/A	-$528K+88.2%	-$1.7M+79.5%	-$1.3M+75.3%	N/A	-$4.5M+58.2%
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$4.5M+58.1%
Interest Expense	N/A	$2K-91.4%	N/A	N/A	N/A	$25K+470.5%	N/A	$475K+19831.5%
Net Income	-$1.2M-19.7%	-$811K+86.7%	N/A	-$473K+90.3%	-$1.0M+73.4%	-$6.1M-114.0%	N/A	-$4.9M+53.8%
EPS (Basic)	-$0.08+11.1%	-$0.07+96.7%	$0.00+100.0%	-$0.04+99.9%	-$0.09+99.7%	-$2.15+92.4%	-$8.17+98.7%	-$36.21-1221.5%
EPS (Diluted)	-$0.08	-$0.07	$0.00+100.0%	-$0.04	-$0.09	-$2.15	-$8.17	-$36.21
Diluted Shares (Avg)	16M	12M	N/A	12M	11M	3M	N/A	134,379

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

HEPA Balance Sheet

HEPA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1410-K
Total Assets	$3.1M+90.2%	$1.6M-91.1%	$18.1M-70.0%	$60.2M-41.8%	$103.6M+112.9%	$48.6M+136.0%	$20.6M+151.7%	$8.2M-55.5%	$18.4M+40.3%	$13.1M+143.7%	$5.4M+168.7%	$2.0M	$2.6M
Current Assets	$3.1M+90.2%	$1.6M-90.8%	$17.5M-69.0%	$56.5M-42.0%	$97.5M+128.6%	$42.6M+196.3%	$14.4M+384.8%	$3.0M-77.5%	$13.2M+67.1%	$7.9M+50.5%	$5.2M+164.6%	$2.0M	$2.6M
Cash & Equivalents	$1.8M+349.8%	$406K-97.3%	$14.8M-71.1%	$51.2M-44.0%	$91.3M+124.3%	$40.7M+192.5%	$13.9M+391.6%	$2.8M-78.2%	$13.0M+75.3%	$7.4M+62.3%	$4.6M+151.0%	$1.8M	$2.5M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Goodwill	N/A	N/A	N/A	$0-100.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M	N/A	N/A	N/A
Total Liabilities	$402K-88.4%	$3.5M-67.8%	$10.8M+4.1%	$10.4M-1.6%	$10.6M+29.9%	$8.1M+62.7%	$5.0M-19.6%	$6.2M-33.4%	$9.3M-20.9%	$11.8M+508.3%	$1.9M-60.7%	$4.9M	$10.0M
Current Liabilities	$299K-90.5%	$3.1M-40.6%	$5.3M-32.9%	$7.9M-3.9%	$8.2M+76.0%	$4.7M+189.7%	$1.6M-43.5%	$2.8M-3.2%	$2.9M-42.1%	$5.1M+162.3%	$1.9M+322.5%	$459K	$260K
Non-Current Liabilities	$103K-69.1%	$333K-94.0%	$5.5M+120.7%	$2.5M+6.5%	$2.4M-32.1%	$3.5M+2.3%	$3.4M+0.6%	$3.4M-47.3%	$6.4M-4.8%	$6.7M	$0-100.0%	$4.5M	$9.7M
Total Equity	$2.7M+243.2%	-$1.9M-125.6%	$7.3M-85.4%	$49.9M-46.4%	$93.0M+129.5%	$40.5M+159.5%	$15.6M+805.4%	$1.7M-81.0%	$9.1M+587.5%	$1.3M-61.7%	$3.4M+217.2%	-$2.9M	-$7.3M
Retained Earnings	-$246.1M-3.5%	-$237.8M-5.9%	-$224.6M-27.8%	-$175.7M-31.6%	-$133.5M-28.2%	-$104.1M-24.3%	-$83.8M-9.2%	-$76.7M-28.9%	-$59.5M-33.4%	-$44.6M-61.6%	-$27.6M-409.4%	-$5.4M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.9M-57.2%	$2.7M-57.2%	$3.1M+90.2%	$3.7M+0.7%	$4.5M-25.0%	$6.3M-60.5%	$1.6M-91.1%	$3.7M-85.1%
Current Assets	$1.9M-57.2%	$2.7M-57.2%	$3.1M+90.2%	$3.7M+5.9%	$4.5M-17.8%	$6.3M-59.1%	$1.6M-90.8%	$3.5M-83.4%
Cash & Equivalents	$1.6M-44.3%	$2.6M-43.3%	$1.8M+349.8%	$2.3M+55.0%	$2.9M+38.3%	$4.6M-65.0%	$406K-97.3%	$1.5M-92.2%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$649K-8.4%	$849K-65.0%	$402K-88.4%	$416K-89.9%	$709K-71.1%	$2.4M-71.4%	$3.5M-67.8%	$4.1M-53.4%
Current Liabilities	$493K-16.9%	$736K-21.4%	$299K-90.5%	$347K-87.2%	$593K-39.2%	$936K-63.6%	$3.1M-40.6%	$2.7M-57.6%
Non-Current Liabilities	$156K+35.0%	$113K-92.4%	$103K-69.1%	$68K-95.1%	$116K-92.1%	$1.5M-74.8%	$333K-94.0%	$1.4M-42.4%
Total Equity	$1.3M-66.3%	$1.9M-52.3%	$2.7M+243.2%	$3.3M+717.4%	$3.8M+6.6%	$3.9M-48.2%	-$1.9M-125.6%	$407K-97.5%
Retained Earnings	-$248.2M-1.3%	-$246.9M-1.2%	-$246.1M-3.5%	-$245.4M-3.9%	-$245.0M-5.9%	-$243.9M-7.2%	-$237.8M-5.9%	-$236.3M-10.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

HEPA Cash Flow Statement

HEPA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1410-K
Operating Cash Flow	-$1.6M	-$3.3M	N/A	-$40.9M-17.0%	-$35.0M-12.0%	-$31.2M-93.2%	-$16.2M-113.7%	-$7.6M+51.6%	-$15.6M+18.4%	-$19.2M-15.8%	-$16.6M-71.2%	-$9.7M-609.6%	-$1.4M	-$684K
Depreciation & Amortization	N/A	N/A	$31K-54.2%	$67K-13.3%	$77K-10.0%	$86K+149.4%	$35K+29.1%	$27K+42.3%	$19K-32.9%	$28K+30.0%	$22K+31.6%	$16K+1138.1%	$1K	N/A
Stock-Based Compensation	N/A	$21K-97.4%	$792K-40.9%	$1.3M-47.5%	$2.6M-45.3%	$4.7M+96.2%	$2.4M+3495.5%	$66K-71.8%	$235K-86.2%	$1.7M+88.5%	$902K-57.4%	$2.1M+985.0%	$195K	$144K
Capital Expenditures	N/A	N/A	N/A	$14K-12.4%	$16K-87.5%	$130K+48.2%	$88K+70.9%	$51K	N/A	$15K+122.8%	$7K-92.1%	$83K+425.5%	$16K	$16K
Free Cash Flow	N/A	N/A	N/A	-$40.9M-16.9%	-$35.0M-11.6%	-$31.4M-92.9%	-$16.3M-113.4%	-$7.6M	N/A	-$19.2M-15.9%	-$16.6M-69.8%	-$9.8M-607.5%	-$1.4M	-$700K
Investing Cash Flow	N/A	-$132K+78.0%	-$600K-4094.6%	-$14K-1.7%	-$14K+89.2%	-$130K-52.0%	-$86K-66.7%	-$51K-5818.8%	$900+106.1%	-$15K+97.1%	-$502K	N/A	N/A	N/A
Financing Cash Flow	$298K	$4.8M+10.9%	$4.3M-3.2%	$4.5M+187.5%	-$5.1M-106.3%	$82.0M+90.4%	$43.1M+130.2%	$18.7M+49.4%	$12.5M-49.4%	$24.8M+24.5%	$19.9M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.4M-1.4%	$579K+151.8%	-$333K+71.1%	-$446K+82.3%	-$1.4M+87.4%	-$1.1M+69.1%	-$1.2M+87.2%	-$2.5M+77.6%
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$0-100.0%
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	$21K-97.1%	N/A	$29K-91.0%
Investing Cash Flow	N/A	N/A	$0	$0	N/A	N/A	$0+100.0%	N/A
Financing Cash Flow	$420K+371.8%	$196K-96.3%	-$160K	-$157K-106.3%	-$155K	$5.3M+186.4%	$0-100.0%	$2.5M

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

HEPA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HEPA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1410-K
Return on Equity	-310.3%	N/A	-672.0%-587.4pp	-84.6%-49.5pp	-35.2%+15.0pp	-50.2%-5.2pp	-45.1%+502.8pp	-547.9%-383.5pp	-164.4%+1125.7pp	-1290.1%-872.9pp	-417.2%	N/A	N/A
Return on Assets	-269.6%	N/A	-270.4%-200.3pp	-70.0%-38.5pp	-31.6%+10.2pp	-41.8%-7.7pp	-34.1%+81.3pp	-115.4%-34.4pp	-81.0%+48.7pp	-129.7%+137.1pp	-266.8%-2.9pp	-263.9%	-370.8%
Current Ratio	10.25+9.7x	0.51-2.8x	3.31-3.9x	7.16-4.7x	11.88+2.7x	9.15+0.2x	8.94+7.9x	1.04-3.4x	4.48+2.9x	1.55-1.2x	2.71-1.6x	4.32	10.11
Debt-to-Equity	0.15	N/A	1.49+1.3x	0.21+0.1x	0.11-0.1x	0.20-0.1x	0.32-3.3x	3.60+2.6x	1.03-7.9x	8.95+8.4x	0.56	N/A	N/A
Asset Turnover	N/A	N/A	0.000.0x	0.000.0x	0.000.0x	0.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-97.6%-70.2pp	-43.7%+113.1pp	N/A	-14.2%+1182.3pp	-27.5%+82.7pp	-156.7%-118.8pp	N/A	-1196.5%-1131.3pp
Return on Assets	-64.8%-41.6pp	-30.0%+66.7pp	N/A	-12.6%+118.3pp	-23.1%+42.2pp	-96.6%-78.8pp	N/A	-131.0%-88.9pp
Current Ratio	3.91-3.7x	3.68-3.1x	10.25+9.7x	10.77+9.5x	7.60+2.0x	6.75+0.8x	0.51-2.8x	1.30-2.0x
Debt-to-Equity	0.51+0.3x	0.46-0.2x	0.15	0.13-10.0x	0.19-0.5x	0.62-0.5x	N/A	10.14+9.6x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
HEPION PHARMS INC HEPA	FY2025	N/A	-$8.3M	N/A	$12.8M	—
REGEN BIOPHARMA INC RGBP	FY2025	$237K	-$1.3M	N/A	$168K	—
EMMAUS LIFE SCIENCES INC EMMA	FY2025	$12.5M	-$7.5M	-60.2%	$4.1M	—
BIO-PATH HOLDINGS INC BPTH	FY2024	N/A	-$9.9M	N/A	N/A	—
LADRX CORPORATION LADX	FY2024	N/A	-$1.6M	N/A	$579K	—

Where HEPION PHARMS INC Ranks

Frequently Asked Questions

Is HEPION PHARMS INC profitable?

No, HEPION PHARMS INC (HEPA) reported a net income of -$8.3M in fiscal year 2025.

What is HEPION PHARMS INC's return on equity (ROE)?

HEPION PHARMS INC (HEPA) has a return on equity of -310.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is HEPION PHARMS INC's operating cash flow?

HEPION PHARMS INC (HEPA) recorded an outflow of $3.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are HEPION PHARMS INC's total assets?

HEPION PHARMS INC (HEPA) had $3.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does HEPION PHARMS INC spend on research and development?

HEPION PHARMS INC (HEPA) invested $446K in research and development during fiscal year 2025.

How many shares does HEPION PHARMS INC have outstanding?

HEPION PHARMS INC (HEPA) had 12M shares outstanding as of fiscal year 2025.

What is HEPION PHARMS INC's current ratio?

HEPION PHARMS INC (HEPA) had a current ratio of 10.25 as of fiscal year 2025, which is generally considered healthy.

What is HEPION PHARMS INC's debt-to-equity ratio?

HEPION PHARMS INC (HEPA) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is HEPION PHARMS INC's return on assets (ROA)?

HEPION PHARMS INC (HEPA) had a return on assets of -269.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is HEPION PHARMS INC's P/E ratio?

HEPION PHARMS INC (HEPA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $12.8M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is HEPION PHARMS INC's price-to-sales ratio?

HEPION PHARMS INC (HEPA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $12.8M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does HEPION PHARMS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, HEPION PHARMS INC (HEPA) held $1.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.3M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is HEPION PHARMS INC's Piotroski F-Score?

HEPION PHARMS INC (HEPA) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are HEPION PHARMS INC's earnings high quality?

HEPION PHARMS INC (HEPA) reported a net loss of $8.3M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can HEPION PHARMS INC cover its interest payments?

HEPION PHARMS INC (HEPA) reported an operating loss of $4.2M against $24K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.